Charles river and curigin collaborate to produce oncolytic rnai gene therapy

Rockville, md.--(business wire)--charles river laboratories international, inc. (nyse: crl) and curigin, a korean biotechnology company developing innovative oncolytic ribonucleic acid interference (rnai) gene therapies, today announced a collaboration for adenoviral vector production. the gene therapy developer will leverage charles river's market-leading expertise in contract development and manufacturing organization (cdmo) solutions to support its preclinical and clinical trials. curigin de.
CRL Ratings Summary
CRL Quant Ranking